Prelude Therapeutics Inc (PRLD)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$5.46+4.00%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · PRLD
Income statement, balance sheet, and cash flow — annual and quarterly history, as reported.
Figures in millions of USD, except per-share and ratios.
| TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | |
|---|---|---|---|---|---|---|---|
| Revenues | |||||||
| Revenues | 22.4 | 12.1 | 7.0 | — | — | — | — |
| Operating Expenses & Income | |||||||
| R&D Expenses | 69.4 | 94.3 | 118.0 | 103.4 | 92.9 | 86.8 | 48.2 |
| Operating Income | (67.4) | (104.6) | (139.7) | (132.3) | (123.5) | (113.7) | (58.8) |
| Earnings from Continuing Operations | |||||||
| Income Tax Expense | — | 0.0 | — | — | — | — | — |
| Net Income | |||||||
| Net Income | (60.5) | (99.5) | (127.2) | (121.8) | (115.4) | (111.7) | (56.9) |
| Per Share | |||||||
| Basic EPS | (0.61) | (1.29) | (1.68) | (2.02) | (2.44) | (2.43) | — |
| Diluted EPS | (0.61) | (1.29) | (1.68) | (2.02) | (2.44) | (2.43) | — |
| Revenue per Share | 0.23 | — | — | — | — | — | — |
| Basic Weighted Avg Shares | 98.4 | 77.0 | 75.8 | 60.4 | 47.4 | 46.0 | — |
| Diluted Weighted Avg Shares | 98.4 | 77.0 | 75.8 | 60.4 | 47.4 | 46.0 | — |
| Supplemental | |||||||
| EBITDA | — | (102.9) | (137.9) | (131.1) | (122.2) | (112.8) | (58.3) |
| EBIT | (67.4) | (104.6) | (139.7) | (132.3) | (123.5) | (113.7) | (58.8) |
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.